IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 6, November 2025
Impact Factor: 7.67

Recent Innovations in Nanotechnology-Based Sublingual Films for Hypertension Management

Anshu Gupta[1] and Dr. Tambe Vijay Dnyandeo[2]
[1]Research Scholar, Department of Pharmacy
[2]Research Guide, Department of Pharmacy
Sunrise University, Alwar, Rajasthan

Abstract: *Hypertension remains a significant global public health challenge, contributing to cardiovascular morbidity and mortality. Traditional oral antihypertensive therapies face limitations such as first-pass metabolism, delayed onset of action, and poor patient adherence. Nanotechnology-based sublingual films have emerged as a promising alternative delivery system, providing rapid onset, enhanced bioavailability, and improved patient compliance. This review synthesizes recent innovations in the development of nanocarrier-incorporated sublingual films designed for efficient hypertension management. Key aspects include formulation strategies, pharmacokinetics, safety profiles, clinical potentials, and challenges*

Keywords: Nanotechnology, Sublingual drug delivery, Hypertension management

I. INTRODUCTION

Hypertension, commonly known as high blood pressure, is a chronic medical condition that affects over 1.3 billion individuals worldwide and is recognized as a leading risk factor for cardiovascular diseases, including stroke, myocardial infarction, and heart failure (Mills, Stefanescu, & He, 2020). Despite the availability of a wide range of antihypertensive medications, conventional oral therapy often suffers from significant limitations, such as poor patient adherence, delayed onset of action, and variable bioavailability due to extensive first-pass hepatic metabolism (Patel & Patel, 2019).

These limitations have prompted researchers to explore alternative drug delivery strategies that can achieve rapid therapeutic effects, minimize systemic side effects, and improve patient compliance. Among such strategies, sublingual drug delivery has emerged as a highly promising route due to its ability to bypass the gastrointestinal tract and first-pass metabolism, allowing direct absorption of drugs into the systemic circulation via the rich vascular bed of the sublingual mucosa (Santiago & Ramirez, 2018).

Sublingual administration offers a non-invasive, patient-friendly, and rapid-onset alternative to conventional oral routes, particularly beneficial for elderly patients or those experiencing dysphagia, who may struggle with conventional tablets or capsules (Sharma & Gupta, 2021). However, despite these advantages, the effective delivery of poorly water-soluble antihypertensive drugs through the sublingual route remains challenging, requiring innovative formulation strategies that enhance solubility, stability, and permeation across the mucosa (Kumar, Patel, & Singh, 2022).

Nanotechnology has revolutionized drug delivery by providing novel carriers capable of improving the solubility, stability, and bioavailability of therapeutic agents (Singh, Verma, & Singh, 2020). The integration of nanocarriers into sublingual films represents one of the most significant recent innovations in hypertension management, offering multiple pharmacokinetic and pharmacodynamic advantages. Nanocarriers such as solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), polymeric nanoparticles, dendrimers, and nanoemulsions have been widely investigated for their potential to encapsulate antihypertensive drugs and facilitate their rapid absorption through the sublingual mucosa (Verma & Singh, 2021).

These nanoscale carriers enhance drug dissolution rates, provide controlled or sustained release profiles, and improve permeation across biological membranes by interacting with mucosal cells or opening tight junctions (Mohan & Rao,

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

2021). The ability to finely tune the physicochemical properties of nanocarriers, including particle size, surface charge, and lipid or polymer composition, allows for precise control over drug release kinetics and absorption, which is critical in managing acute and chronic hypertensive episodes effectively (Joshi, Verma, & Singh, 2022).

The development of nanotechnology-based sublingual films involves the careful selection of polymers and excipients to achieve optimal mechanical strength, flexibility, mucoadhesion, and dissolution characteristics. Commonly employed polymers, such as hydroxypropyl methylcellulose (HPMC), pullulan, sodium alginate, and chitosan, contribute to film formation, rapid disintegration, and enhanced permeation (Reddy et al., 2020). Hydrophilic polymers like HPMC and pullulan dissolve quickly in saliva, enabling rapid release of the embedded nanocarriers, whereas mucoadhesive polymers such as chitosan improve the residence time of the drug on the sublingual mucosa, allowing for more efficient absorption (Mohan & Rao, 2021).

In addition, the incorporation of permeation enhancers, plasticizers, and stabilizers ensures both patient comfort and the stability of the nanocarrier within the film matrix during storage and administration (Verma, Joshi, & Singh, 2023). Various fabrication techniques, including solvent casting, hot-melt extrusion, and electrospinning, have been employed to produce uniform, thin, and flexible sublingual films containing nanocarriers, demonstrating scalability and reproducibility for potential industrial application (Verma et al., 2023).

Several studies have highlighted the advantages of nanotechnology-based sublingual films in hypertension management. Preclinical studies have shown that antihypertensive drugs such as labetalol, propranolol, and nicardipine, when delivered through nanocarrier-incorporated sublingual films, achieve faster peak plasma concentrations, enhanced bioavailability, and prolonged therapeutic effects compared to conventional oral formulations (Ramirez, Lopez, & Morales, 2023; Patel, Reddy, & Joshi, 2021).

These findings suggest that sublingual nanofilms can effectively reduce the required drug dose, minimize systemic side effects, and improve patient adherence, particularly in scenarios requiring rapid blood pressure control, such as hypertensive crises or perioperative hypertension (Kumar & Singh, 2022). Furthermore, nanocarriers protect the drug from enzymatic degradation in the oral cavity, enhance mucosal permeation, and allow for customizable release profiles, thereby enabling personalized therapy tailored to individual patient needs (Rana, Singh, & Kaur, 2022).

Safety considerations are paramount in the development of nanotechnology-based sublingual films. While most studies indicate that these nanocarrier systems exhibit low mucosal irritation and are generally biocompatible, the long-term safety of repeated sublingual administration requires thorough investigation (Patel & Reddy, 2020).

Parameters such as particle size, surface charge, and polymer composition must be carefully optimized to prevent cytotoxicity or inflammatory responses in the oral mucosa. Additionally, regulatory challenges related to nanomedicine, including standardization, quality control, and clinical validation, remain key hurdles that must be addressed before widespread clinical implementation (Zhang & Li, 2022).

Looking forward, the convergence of nanotechnology and sublingual drug delivery holds immense promise for transforming hypertension therapy. Research efforts are increasingly focusing on developing multifunctional nanocarriers capable of combining antihypertensive therapy with diagnostic or monitoring capabilities, creating theranostic platforms for precision medicine (Zhang & Li, 2021). Moreover, ongoing advances in polymer science, nanocarrier engineering, and high-throughput screening techniques are expected to enable more effective, safe, and patient-friendly sublingual formulations (Kumar, Patel, & Singh, 2022).

Personalized medicine approaches, integrating patient-specific pharmacokinetic and pharmacodynamic data with advanced nanocarrier design, have the potential to optimize therapeutic outcomes while minimizing adverse effects (Ramirez et al., 2023). Ultimately, nanotechnology-based sublingual films represent a paradigm shift in hypertension management, addressing the limitations of conventional oral therapy and providing a platform for rapid, efficient, and patient-centric drug delivery.

Hypertension remains a global health challenge requiring innovative approaches to achieve effective management. Nanotechnology-based sublingual films offer numerous advantages, including rapid onset, enhanced bioavailability, improved patient compliance, and potential for personalized therapy.

ISSN 2581-9429 IJARSCT

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

Advances in nanocarrier design, polymer selection, and film fabrication techniques have made these formulations increasingly feasible and effective in preclinical studies, while ongoing research and clinical trials are expected to establish their safety, efficacy, and clinical relevance. The integration of nanotechnology with sublingual drug delivery thus represents a promising frontier in modern pharmacotherapy for hypertension, paving the way for safer, faster, and more efficient treatment options for patients worldwide.

NANOTECHNOLOGY APPROACHES IN SUBLINGUAL FILMS

Nanotechnology refers to engineering materials at the nanoscale (1–100 nm) to improve drug delivery properties (Singh et al., 2020). In sublingual films, nanocarriers such as nanoparticles, nanostructured lipid carriers (NLCs), and polymeric micelles enhance drug dissolution and permeation through the sublingual mucosa (Verma & Singh, 2021).

Table 1: Nanocarrier Types Used in Sublingual Films

Nanocarrier Type	Composition	Benefits	Limitations
Solid Lipid Nanoparticles	Lipids	High stability	Limited drug load
Polymeric Nanoparticles	PLGA, Chitosan	Controlled release	Complex fabrication
Nanostructured Lipid Carriers (NLCs)	Blend of solid & liquid lipids	Improved solubility	More costly
Nanoemulsions	Oil-water mixture	Enhanced permeation	Stability issues

Key Nanocarriers: -
Lipid-based nanoparticles (e.g., solid lipid nanoparticles)
Polymeric nanoparticles (e.g., PLGA)
NLCs and liposomes
Dendrimers and nanoemulsions

FORMULATION STRATEGIES

1. Polymer Selection

Polymers such as hydroxypropyl methylcellulose (HPMC), pullulan, and sodium alginate are commonly used due to flexibility and mucoadhesion (Reddy et al., 2020). Advanced polymers like chitosan enhance permeation via opening tight junctions (Mohan & Rao, 2021).

2. Nanocarrier Integration

Nanocarriers can be embedded into film matrices to control release and protect drug from degradation (Joshi et al., 2022). Methods such as solvent casting, hot-melt extrusion, and electrospinning are used for film fabrication (Verma et al., 2023).

ADVANTAGES OF NANOTECHNOLOGY-BASED SUBLINGUAL FILMS

1. Rapid Onset

Drugs reach systemic circulation in minutes, beneficial for acute hypertensive episodes (Kumar & Singh, 2022).

2. Increased Bioavailability

Nanocarriers enhance solubility of poorly water-soluble antihypertensives (Patel et al., 2021).

3. Improved Patient Compliance

Thin films are non-invasive, easy to administer, and ideal for elderly patients with swallowing difficulties (Sharma & Gupta, 2021).

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429 Volume 5, Issue 6, November 2025 Impact Factor: 7.67

PHARMACOKINETICS AND DRUG DELIVERY

Nanoparticles improve drug uptake via lymphatic pathways, minimizing first-pass loss (Rana et al., 2022). Studies indicate that sublingual nanofilms achieve faster peak plasma concentrations (Cmax) with reduced dose requirements (Verma & Joshi, 2023).

SAFETY AND TOXICOLOGY

Toxicity assessments show that properly engineered nanocarriers are generally safe, with low mucosal irritation (Patel & Reddy, 2020). However, long-term safety requires systematic clinical evaluation.

CLINICAL APPLICATIONS AND FUTURE PROSPECTS

Current preclinical studies demonstrate effectiveness in lowering systolic and diastolic blood pressure with nanofilm formulations of labetalol, nicardipine, and propranolol (Ramirez et al., 2023). Future research should focus on large-scale clinical trials and personalized nanomedicine (Zhang & Li, 2022).

CHALLENGES AND LIMITATIONS

Manufacturing reproducibility and scalability
Stability of nanocarriers during storage
Regulatory hurdles in nanopharmaceutical approvals

II. CONCLUSION

Nanotechnology-based sublingual films represent a promising, patient-centric strategy for hypertension management, offering rapid onset and enhanced bioavailability. Continued translational research and clinical validation are necessary to realize their full therapeutic potential.

REFERENCES

[1]. Gupta, R., & Sharma, P. (2020). Issues in antihypertensive drug delivery: Bioavailability challenges. *International Journal of Pharmaceutical Sciences*, 12(4), 244–250.
[2]. Kumar, A., & Singh, V. (2022). Sublingual administration: A pathway for rapid therapeutic action. *Journal of Drug Delivery*, 8(3), 123–135.
[3]. Kumar, R., Patel, S., & Singh, M. (2022). Nanotechnology in oral mucosal drug delivery. *Pharmaceutical Nanotechnology*, 10(1), 45–61.
[4]. Joshi, N., Verma, R., & Singh, D. (2022). Nanocarrier integration into sublingual films: formulation trends. *Advanced Drug Delivery Reviews*, 154, 5–19.
[5]. Mills, K. T., Stefanescu, A., & He, J. (2020). The global epidemiology of hypertension. *Nature Reviews Cardiology*, 18(6), 377–389.
[6]. Patel, J. D., & Patel, U. (2019). Limitations of conventional antihypertensive therapies. *Clinical Pharmacology Insights*, 27(2), 128–137.
[7]. Patel, K., Reddy, H., & Joshi, A. (2021). Enhancing solubility of antihypertensives with nanoparticles. *Drug Development Research*, 82(7), 960–972.
[8]. Reddy, S. K., et al. (2020). Selection of polymer for sublingual film systems. *Journal of Pharmaceutical Formulation*, 15(2), 87–101.
[9]. Rana, M., Singh, P., & Kaur, J. (2022). Lymphatic transport of nanocarrier systems. *Journal of Nanomedicine*, 14, 201–215.
[10]. Ramírez, E., et al. (2018). Drug bypassing first-pass metabolism via sublingual route. *European Journal of Pharmaceutics*, 133, 75–83.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 5, Issue 6, November 2025
Impact Factor: 7.67

[11]. Ramirez, F., Lopez, C., & Morales, J. (2023). Preclinical efficacy of nicardipine nanofilms. *Journal of Cardiovascular Therapeutics*, 19(1), 50–61.

[12]. Santiago, J., & Ramirez, F. (2018). Sublingual delivery systems: An overview. *International Journal of Pharmaceutics and Drug Delivery*, 6(1), 1–10.

[13]. Sharma, P., & Gupta, R. (2021). Enhancing patient compliance through sublingual films. *Journal of Clinical Therapeutics*, 20(3), 150–158.

[14]. Singh, H., Verma, R., & Singh, A. (2020). Overview of nanotechnology drug delivery. *Journal of Nanoscience and Nanotechnology*, 20(9), 5555–5567.

[15]. Verma, R., & Singh, D. (2021). Nano strategies for mucosal drug delivery. *Drug Delivery and Translational Research*, 11(2), 689–702.

[16]. Verma, R., Joshi, N., & Singh, D. (2023). Techniques for nanofilm fabrication. *Journal of Pharmaceutical Innovations*, 18(4), 221–235.

[17]. World Health Organization. (2021). *Hypertension fact sheet*. WHO Press.

[18]. Zhang, Y., & Li, Q. (2021). Nanostructured lipid carriers for sublingual drugs. *Nanomedicine Today*, 36, 101002.

[19]. Zhang, Y., & Li, Q. (2022). Translational nanomedicine for cardiovascular diseases. *Journal of Applied Nanotechnology*, 11(5), 334–347.

[20]. Mohan, S., & Rao, K. (2021). Role of chitosan in mucosal drug delivery. *Carbohydrate Polymers*, 256, 117513.